Investigating how broadly neutralizing antibodies help control HIV-1 infection
Multi-Omics Correlates of Broadly Neutralizing Antibody Efficacy
This study is looking at how well certain antibodies can help control HIV-1 infection after people stop taking their regular medication, and it's for anyone living with HIV who wants to learn more about new treatment options and potential cures.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beth Israel Deaconess Medical Center NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11084519 on NIH RePORTER |
What this research studies
This research explores the effectiveness of broadly neutralizing antibodies (bNAbs) in controlling HIV-1 infection after stopping antiretroviral therapy (ART). It aims to understand the mechanisms behind bNAb efficacy, including their direct antiviral effects and their ability to enhance the immune response. By analyzing clinical specimens from HIV-1-infected individuals, the study will assess various biological factors that correlate with successful long-term viral control. This comprehensive approach may lead to improved strategies for HIV-1 treatment and potential cures.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV-1 who are currently on ART and have achieved viral suppression.
Not a fit: Patients who are not infected with HIV-1 or those who have not responded to ART may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for HIV-1, potentially allowing patients to maintain viral control without continuous ART.
How similar studies have performed: Previous research has shown promising results with similar approaches using broadly neutralizing antibodies in HIV-1 treatment, indicating potential for success.
Where this research is happening
Boston, United States
- Beth Israel Deaconess Medical Center — Boston, United States (Active)
Researchers
- Principal investigator: Barouch, Dan H. — Beth Israel Deaconess Medical Center
- Study coordinator: Barouch, Dan H.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.